Your browser doesn't support javascript.
loading
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Lode, Holger N; Ehlert, Karoline; Huber, Stephanie; Troschke-Meurer, Sascha; Siebert, Nikolai; Zumpe, Maxi; Loibner, Hans; Ladenstein, Ruth.
Afiliación
  • Lode HN; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany. Holger.Lode@med.uni-greifswald.de.
  • Ehlert K; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Huber S; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Troschke-Meurer S; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Siebert N; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Zumpe M; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Loibner H; Anyxis Immuno Oncology, Vienna, Austria.
  • Ladenstein R; Department of Studies and Statistics for Integrated Research and Projects, Children's Cancer Research Institute, Vienna, Austria.
Br J Cancer ; 129(11): 1780-1786, 2023 11.
Article en En | MEDLINE | ID: mdl-37813959
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neuroblastoma Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neuroblastoma Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania